Skip to main content
. Author manuscript; available in PMC: 2006 Jan 25.
Published in final edited form as: Br J Pharmacol. 2003 Oct;140(4):637–646. doi: 10.1038/sj.bjp.0705493

Figure 3.

Figure 3

Mean change in peak walking time among the three different treatment groups in the TRAFFIC study of peripheral artery disease (Lederman et al., 2002): placebo, single bolus of FGF-2 (30 μg kg−1), or double bolus of FGF-2 (30 μg kg−1). By intention-to-treat analysis (nonparametric analysis), the difference in PWT was different between all groups (P<0.034). When compared with placebo, patients treated with a single bolus of FGF-2 had higher PWT (pairwise comparison).